Endo settled off-label charges for $192 million, resolving civil "whistleblower" suits filed by two sales reps and a physician.
The FDA commissioner said the agency is doing its job, not picking a fight, when it inspects drug-making facilities, and that India must take an active role for a harmonious supply chain.
The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.
Gaming does not trivialize the patient's experience of a chronic disease
Success cures fear, and success is born out of focus and hard work
FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals
The firm has vowed to appeal an FDA rejection that otherwise complicates its bid to expand in multiple sclerosis.
The FDA wants more data for the proposed canagliflozin-metformin medication mix.